Harmon Cyrus 4
4 · Olema Pharmaceuticals, Inc. · Filed Jan 16, 2026
Insider Transaction Report
Form 4
Harmon Cyrus
Director
Transactions
- Sale
Common Stock
[F1]2026-01-14$29.12/sh−3,489$101,600→ 737,770 total
Holdings
- 117,028(indirect: See Footnote)
Common Stock
[F2]
Footnotes (2)
- [F1]The weighted average sale price for the transaction reported was $29.12, and the range of prices were between $29.00 and $29.23. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F2]The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.
Signature
/s/ Shane Kovacs, Attorney-in-Fact|2026-01-16